Article
Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.
Leukemia & lymphoma - 1 Jan 2016
Shadman Mazyar, Gopal Ajay K, Kammerer Britt, Becker Pamela S, Maloney David G, Pender Barbara, Shustov Andrei R, Press Oliver W, Pagel John M
Abstract excerpt
Despite initial responses to chemoimmunotherapy, relapse and minimal residual disease (MRD) remain major issues in treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients. We administered (131)I-tositumomab to patients in complete response (CR) or partial response (PR) after induction chemotherapy. Toxicities and rate of PR to CR conversion and MRD elimination were assessed three...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.